Salivary duct carcinoma responding to trastuzumab-based therapy: Case report and review of the literature

Head and Neck

Volumn 35, Issue 12, 2013, Pages

  Krishnamurthy, Jairam ^a   Krishnamurty, Devi Mukkai ^b   Baker, John J ^c   Zhen, Weining ^c   Lydiatt, Daniel ^a   Ganti, Apar Kishor ^a,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

chemotherapy; HER 2 neu; salivary duct carcinoma; survival; trastuzumab

Indexed keywords

CISPLATIN; DOCETAXEL; TRASTUZUMAB;

AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CERVICAL LYMPHADENOPATHY; HUMAN; LUNG METASTASIS; MALE; MEDIASTINUM LYMPH NODE; METASTASIS; MULTIPLE CYCLE TREATMENT; NECK DISSECTION; PAROTIDECTOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SALIVARY GLAND CARCINOMA; TREATMENT RESPONSE;

CHEMOTHERAPY; HER-2/NEU; SALIVARY DUCT CARCINOMA; SURVIVAL; TRASTUZUMAB;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHATIC METASTASIS; MALE; NECK DISSECTION; PAROTID NEOPLASMS; RECEPTOR, ERBB-2; SALIVARY DUCTS;

EID: 84888002215     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23307     Document Type: Article

References (35)

1. Kleinsasser O, Klein HJ, Hübner G,. [Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma]. [Article in German] Arch Klin Exp Ohren Nasen Kehlkopfheilkd 1968; 192: 100-105.
2. Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Löning T,. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 2005; 103: 2526-2533.
3. Seifert G, Batsakis JG, Brocheriou C, Cardesa A, Dardick I, Ellis GL,. World Health Organisation. Histological typing of salivary gland tumors. 2nd ed. New York: Springer, 1991.
4. Gal R, Strauss M, Zohar Y, Kessler E,. Salivary duct carcinoma of the parotid gland. Cytologic and histopathologic study. Acta Cytol 1985; 29: 454-456.
5. Barnes L, Rao U, Krause J, Contis L, Schwartz A, Scalaogna P,. Salivary duct carcinoma. Part I. A clinicopathological evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol 1994; 78: 64-73.
6. Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD,. Salivary duct carcinoma. Clinicopathologic and immunochemical review of 26 cases. Cancer 1996; 77: 223-230.
7. Simpson RHW, Di Palma S,. Selected recent advances in the pathology of salivary neoplasms. Diagn Histopathol 2010; 16: 276-286.
8. Guzzo M, Di Palma S, Grandi C, Molinari R,. Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck 1997; 19: 126-133.
9. Yarden Y,. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37 Suppl 4: S3-S8.
10. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
11. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P,. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993; 11: 1936-1942.
12. Glisson B, Colevas AD, Haddad R, et al. HER2 expression in salivary gland carcinomas: dependence on histologic subtype. Clin Cancer Res 2004; 10: 944-946.
13. Nabili V, Tan JW, Bhuta S, Sercarz JA, Head CS,. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck 2007; 29: 907-912.
14. Kaidar-Person O, Billan S, Kuten A,. Targeted therapy with trastuzumab for advanced salivary duct carcinoma: case report and literature review. Med Oncol 2012; 29: 704-706.
15. Nashed M, Casasola RJ,. Biological therapy of salivary duct carcinoma. J Laryngol Otol 2009; 123: 250-252.
16. Prat A, Parera M, Reyes V, et al. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck 2008; 30: 680-683.
17. Haddad R, Posner MR,. Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine. Clin Adv Hematol Oncol 2003; 1: 226-228.
18. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003; 39: 724-727.
19. Felix A, El-Naggar AK, Press MF, et al. Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol 1996; 27: 561-566.
20. Gal R, Strauss M, Zohar Y, Kessler E,. Salivary duct carcinoma of the parotid gland. Cytologic and histopathologic study. Acta Cytol 1985; 29: 454-456.
21. Delgado R, Vuitch F, Albores-Saavedra J,. Salivary duct carcinoma. Cancer 1993; 72: 1503-1512.
22. Sugano S, Mukai K, Tsuda H, et al. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope 1992; 102: 923-927.
23. Semba K, Kamata N, Toyoshima K, Yamamoto T,. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci U S A 1985; 82: 6497-6501.
24. Nagao T, Sugano I, Ishida Y, et al. Salivary gland malignant myoepithelioma: a clinicopathologic and immunohistochemical study of ten cases. Cancer 1998; 83: 1292-1299.
25. Hellquist HB, Sundelin K, Di Bacco A, Tytor M, Manzotti M, Viale G,. Tumour growth fraction and apoptosis in salivary gland acinic cell carcinomas. Prognostic implications of Ki-67 and bcl-2 expression and of in situ end labelling (TUNEL). J Pathol 1997; 181: 323-329.
26. Nagao T, Sugano I, Ishida Y, et al. Basal cell adenocarcinoma of the salivary glands: comparison with basal cell adenoma through assessment of cell proliferation, apoptosis, and expression of p53 and bcl-2. Cancer 1998; 82: 439-447.
27. Etges A, Pinto DS Jr, Kowalski LP, Soares FA, Araújo VC,. Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumor. J Clin Pathol 2003; 56: 914-918.
28. Skálová A, Stárek I, Vanecek T, et al. Expression of Her-2/neu gene and protein in salivary duct carcinoma of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 2003; 42: 348-356.
29. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ,. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96: 739-749.
30. Sato N, Sano M, Tabei T, et al. Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study. Breast Cancer 2006; 13: 166-171.
31. Barnes L, Rao U, Contis L, Krause J, Schwartz A, Scalamogna P,. Salivary duct carcinoma. Part II. Immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein. Oral Surg Oral Med Oral Pathol 1994; 78: 74-80.
32. Locati LD, Perrone F, Losa M, et al. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol 2009; 45: 986-990.
33. Moriki T, Ueta S, Takahashi T, Mitani M, Ichien M,. Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer 2001; 93: 344-350.
34. Locati LD, Quattrone P, Bossi P, Marchiano AV, Cantù G, Licitra L,. A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann Oncol 2003; 14: 1327-1328.
35. Jaspers HC, Verbist BM, Schoffelen R, et al. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol 2011; 29: e473-e476.